Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 11Genitourinary 4Thoracic 3Tumor-Agnostic 2Other hematologic neoplasm 2Lymphoid 2Gynecologic 2Sarcoma 1Head & Neck 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Ovarian Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Chondrosarcoma 1Breast Neoplasms 1

Interventions

Paclitaxel 268Carboplatin 264Cisplatin 194Bevacizumab 135pembrolizumab 99Surveys and Questionnaires 84Radiotherapy 77Cyclophosphamide 75olaparib 67Blood Specimen Collection 65Drug Therapy 62Hyperthermic Intraperitoneal Chemotherapy 60Gemcitabine 60niraparib 56Topotecan 56Brachytherapy 54liposomal doxorubicin 52Taxes 47Docetaxel 46Magnetic Resonance Spectroscopy 43Letrozole 36Cytoreduction Surgical Procedures 36Filgrastim 33Biopsy 33Surgical Procedures, Operative 32durvalumab 31Specimen Handling 31Doxorubicin 31Nivolumab 30Albumin-Bound Paclitaxel 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × capivasertib × Gynecologic × Clear all
NCT05039801 2026-06-01

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Recruiting
54 enrolled
DermatologicGynecologicHead & NeckSarcoma

Squamous Cell Carcinoma of Head and Neck, Chondrosarcoma, Melanoma, Ovarian Neoplasms, Endometrial Neoplasms

NCT02208375 2025-12-31

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
159 enrolled
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡